<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773539</url>
  </required_header>
  <id_info>
    <org_study_id>CRYO-BAD-KROZ</org_study_id>
    <nct_id>NCT00773539</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy</brief_title>
  <acronym>CRYO-RF</acronym>
  <official_title>Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herz-Zentrums Bad Krozingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CryoCath Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herz-Zentrums Bad Krozingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transvenous pulmonary vein (PV) isolation using radiofrequency energy is an effective
      treatment for atrial fibrillation (1-4). However, rare but potentially life threatening
      complications such as thromboembolism (5), PV stenosis (5-10), left atrium-oesophageal
      fistula (11) and inflammatory syndromes (12) have been described. In preliminary studies an
      alternate approach using cryoenergy induces less endothelial disruption/ thrombus formation
      (13), preserves the extra cellular matrix and creates lesions with well-delineated border
      zones (14). Therefore, cryoenergy seems to be the ideal form of energy to safely perform PV
      isolation.

      We therefore hypothesise that in the setting of PV isolation for the treatment of atrial
      fibrillation (AF) cryoenergy is less traumatic and therefore reduces systemic inflammatory
      responses compared to radiofrequency energy.

      78 patients presenting with symptomatic intermittent or persistent AF will be randomised to
      PV isolation with either radiofrequency (26 patients open irrigated tip, 26 patients closed
      irrigated tip) or cryoenergy (26 patients with cryoballoon). Systemic markers of cell damage
      and inflammatory response (t-troponin, CK, CK-MB, vWF, PAI-1, micro particles, platelet
      activation/overall function, CRP, IL-6, IL-8, IL-10, TNF alpha, procalcitonin) will be
      monitored before, during and 48h after the procedure. Further endpoints include time to
      PV-isolation and procedure related complications. Six month clinical follow-up will focus on
      freedom from AF and cardiovascular events.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of platelet function (number of patients with an increase of more than 100% in platelets positive for either P-selectin or activated GP IIb/IIIa)</measure>
    <time_frame>before, at the end of intervention, 6, 24 and 48 hours later.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parameters of inflammation and tissue damage, the time to achieve PV-Isolation, freedom from AF.</measure>
    <time_frame>before, during and 6 months after procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Atrial Fibrillation Ablation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI using an open irrigated tip catheter</intervention_name>
    <description>transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI using a closed irrigated tip catheter</intervention_name>
    <description>transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI using a cryoballoon</intervention_name>
    <description>transseptal PVI using the cryoballoon from CRYOCATH</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 75 years

          -  Symptomatic drug refractory (more than 2 antiarrhythmic drugs) paroxysmal or
             persistent AF

          -  Documentation of AF on 12 lead ECG and/ or Holter

          -  Left atrium of less than 55 mm

          -  Informed consent signed by the patient

        Exclusion Criteria:

          -  Previous Ablation or operation for AF

          -  Contra-indication for heart catheterisation

          -  Cardioversion for AF during the 2 weeks before the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Arentz, MD</last_name>
    <phone>004976334020</phone>
    <email>thomas.arentz@herzzentrum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dietmar Trenk</last_name>
    <phone>004976334020</phone>
    <email>dietmar.trenk@herzzentrum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herz-Zentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Arentz, MD</last_name>
      <phone>004976334020</phone>
      <email>thomas.arentz@herzzentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Reinhold Weber, MD</last_name>
      <phone>004976334020</phone>
      <email>reinhold.weber@herzzentrum.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>October 14, 2008</last_update_submitted>
  <last_update_submitted_qc>October 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Thomas Arentz</name_title>
    <organization>Herz-Zentrum Bad Krozingen</organization>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>pulmonary veins</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

